Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients

Annals of Surgical Oncology

Volumn 17, Issue 12, 2010, Pages 3252-3258

  Hall, Carolyn ^a   Krishnamurthy, Savitri ^a   Lodhi, Ashutosh ^a   Mosalpuria, Kailash ^a   Kuerer, Henry M ^a   Meric Bernstam, Funda ^a   Bedrosian, Isabelle ^a   Hunt, Kelly K ^a   Lucci, Anthony ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN ANTIBODY; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CHI SQUARE TEST; DISSEMINATED CANCER; FEMALE; FISHER EXACT TEST; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 78650965947     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1160-7     Document Type: Article

References (22)

1. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10.1038/35021093 10963602
2. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 1:CAS:528:DC%2BD3MXntVGmsbo%3D 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
3. F Bertucci P Finetti N Cervera, et al. 2008 How basal are triple-negative breast cancers? Int J Cancer 123 236 240 1:CAS:528:DC%2BD1cXmtlantbg%3D 10.1002/ijc.23518 18398844 (Pubitemid 351705215)
4. RC Millikan B Newman CK Tse, et al. 2008 Epidemiology of basal-like breast cancer Breast Cancer Res Treat 109 123 139 10.1007/s10549-007-9632-6 17578664 (Pubitemid 351538762)
5. MC Cheang D Voduc C Bajdik, et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 1368 1376 1:CAS:528:DC%2BD1cXislSrs7o%3D 10.1158/1078-0432. CCR-07-1658 18316557 (Pubitemid 351413917)
6. R Dent M Trudeau KI Pritchard, et al. 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 10.1158/1078-0432.CCR-06-3045 17671126 (Pubitemid 47219710)
7. JM Dolle JR Daling E White, et al. 2009 Risk factors for triple-negative breast cancer in women under the age of 45 years Cancer Epidemiol Biomarkers Prev 18 1157 1166 10.1158/1055-9965.EPI-08-1005 19336554
8. M Tischkowitz JS Brunet LR Begin, et al. 2007 Use of immunohistochemical markers can refine prognosis in triple negative breast cancer BMC Cancer 7 134 10.1186/1471-2407-7-134 17650314 (Pubitemid 47272190)
9. S Nofech-Mozes M Trudeau HK Kahn, et al. 2009 Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers Breast Cancer Res Treat 118 131 137 10.1007/s10549-008-0295-8 19189211
10. C Liedtke C Mazouni KR Hess, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147 18250347
11. S Braun K Pantel P Muller, et al. 2000 Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer N Engl J Med 342 525 533 1:STN:280:DC%2BD3c7jt1ejsw%3D%3D 10.1056/ NEJM200002243420801 10684910 (Pubitemid 30117892)
12. S Braun FD Vogl B Naume, et al. 2005 A pooled analysis of bone marrow micrometastasis in breast cancer N Engl J Med 353 793 802 1:CAS:528: DC%2BD2MXovVKlu7s%3D 10.1056/NEJMoa050434 16120859 (Pubitemid 41215488)
13. RJ Cote PP Rosen ML Lesser, et al. 1991 Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases J Clin Oncol 9 1749 1756 1:STN:280:DyaK38%2FhsVWntQ%3D%3D 1919627
14. G Gebauer T Fehm E Merkle, et al. 2001 Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up J Clin Oncol 19 3669 3674 1:STN:280:DC%2BD3MvlvV2rsg%3D%3D 11504748
15. LA Carey CM Perou CA Livasy, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492 2502 1:CAS:528:DC%2BD28XlsV2rtLw%3D 10.1001/jama.295.21.2492 16757721 (Pubitemid 43854964)
16. Edge SB. AJCC cancer staging manual. Berlin: Springer; 2010.
17. V Muller N Stahmann S Riethdorf, et al. 2005 Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity Clin Cancer Res 11 3678 3685 10.1158/1078-0432.CCR-04-2469 15897564 (Pubitemid 40685584)
18. M Balic H Lin L Young, et al. 2006 Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype Clin Cancer Res 12 5615 5621 1:CAS:528:DC%2BD28XhtVartb3L 10.1158/1078-0432.CCR-06-0169 17020963 (Pubitemid 44629587)
19. S Becker E Solomayer G Becker-Pergola, et al. 2007 Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients Breast Cancer Res Treat 106 239 243 10.1007/s10549-006-9484-5 17260094 (Pubitemid 350045008)
20. MJ Slade A Singh BM Smith, et al. 2005 Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years Int J Cancer 114 94 100 1:CAS:528:DC%2BD2MXhtFCns7c%3D 10.1002/ijc.20655 15523696 (Pubitemid 40194313)
21. W Janni B Rack C Schindlbeck, et al. 2005 The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence Cancer 103 884 891 10.1002/cncr.20834 15666325 (Pubitemid 40270064)
22. LA Carey EC Dees L Sawyer, et al. 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 1:CAS:528:DC%2BD2sXkt1enur0%3D 10.1158/1078-0432.CCR-06-1109 17438091 (Pubitemid 46698581)